Edition:
India

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

5.24EUR
5 Aug 2020
Change (% chg)

€0.00 (+0.00%)
Prev Close
€5.24
Open
€5.28
Day's High
€5.38
Day's Low
€5.12
Volume
51,042
Avg. Vol
60,147
52-wk High
€7.19
52-wk Low
€2.91

Latest Key Developments (Source: Significant Developments)

Medigene Enters Phase I Clinical Development With Its Tcr-T Immunotherapy Mdg1021 In Hematological Cancers
Wednesday, 24 Jun 2020 

June 23 (Reuters) - Medigene AG ::PTA-NEWS: MEDIGENE AG: MEDIGENE ENTERS PHASE I CLINICAL DEVELOPMENT WITH ITS TCR-T IMMUNOTHERAPY MDG1021 IN HEMATOLOGICAL CANCERS.MEDIGENE AG - RECEIVED APPROVAL FROM DUTCH REGULATORY AUTHORITY TO BEGIN FIRST CLINICAL TRIAL OF MDG1021. MDG1021.MEDIGENE AG - PHASE I CLINICAL TRIAL IN CANCER PATIENTS SUFFERING FROM RELAPSE/PERSISTENCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.  Full Article

Medigene: Clinical Data From Interim Analysis Of Phase I/II Trial With DC Vaccine
Monday, 17 Jun 2019 

June 17 (Reuters) - Medigene AG ::INTERIM ANALYSIS FROM ONGOING PHASE I/II CLINICAL TRIAL WITH DC VACCINES IN AML PATIENTS PRESENTED AT EHA.EXCELLENT SAFETY AND TOLERABILITY PROFILE.ENCOURAGING DATA ON OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL.VERY GOOD FEASIBILITY FOR MANUFACTURE OF VACCINES FROM PATIENT-DERIVED CELLS.  Full Article

Medigene Sells Remaining Rights And Inventories Of Veregen To Aresus
Monday, 8 Apr 2019 

April 8 (Reuters) - Medigene AG ::MEDIGENE SELLS REMAINING RIGHTS AND INVENTORIES OF VEREGEN® TO ARESUS PHARMA.ALL EXISTING RELEVANT CONTRACTS WITH DISTRIBUTION PARTNERS AND EXTERNAL SERVICE PROVIDERS WILL BE TRANSFERRED FROM MEDIGENE TO ARESUS.COMPLETES TRANSFORMATION INTO A PURE IMMUNOTHERAPY COMPANY.MEDIGENE WILL RECEIVE UP TO APPROXIMATELY EUR 7.75 MILLION FROM ARESUS FOR REMAINING VEREGEN® RIGHTS AND ALL EXISTING API STOCK.MEDIGENE'S EBITDA WILL BE AFFECTED BY A NON-CASH EFFECTIVE LOSS BETWEEN EUR 4 AND 5 MIO.EXPECTED PAYMENTS ARE RECOGNIZED AS RECEIVABLES AND DISCOUNTED IN ACCORDANCE WITH INTERNATIONAL FINANCIAL REPORTING STANDARDS.MEDIGENE WILL UPDATE ITS FINANCIAL GUIDANCE WITH RESPECT TO REVENUE AND EBITDA WITH ISSUING ITS QUARTERLY STATEMENT.CLOSING OF TRANSACTION INCLUDING TRANSFER OF RIGHTS IS PLANNED FOR MID-APRIL 2019.  Full Article

Medigene And Roivant Affiliate Cytovant Establish Strategic Partnership
Thursday, 4 Apr 2019 

April 4 (Reuters) - Medigene AG ::PTA-ADHOC: MEDIGENE AG: MEDIGENE AND ROIVANT AFFILIATE CYTOVANT ESTABLISH STRATEGIC RESEARCH AND DEVELOPMENT PARTNERSHIP FOR CELLULAR THERAPIES IN ASIA.MEDIGENE WILL RECEIVE AN OVERALL UPFRONT PAYMENT OF USD 10 MILLION AS WELL AS POTENTIAL DEVELOPMENT.MEDIGENE WILL BE ELIGIBLE TO RECEIVE ROYALTY PAYMENTS ON NET SALES OF PRODUCTS IN A LOW DOUBLE-DIGIT PERCENTAGE IN RELEVANT COUNTRIES.CYTOVANT WILL REIMBURSE ALL RESEARCH AND DEVELOPMENT COSTS INCURRED BY MEDIGENE WITHIN COLLABORATION..TO RECEIVE COMMERCIAL MILESTONE PAYMENTS WHICH IN AGGREGATE COULD TOTAL OVER USD 1 BILLION.  Full Article

Medigene FY Total Revenues Amounted To EUR 7.8 Mln In 2018
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Medigene AG ::FY TOTAL REVENUES AMOUNTED TO EUR 7.8 M IN 2018 (2017: EUR 8.9 M).FY EBITDA LOSS OF EUR 16.3 M (2017: EUR 14.6 M).CASH AND CASH EQUIVALENTS (LIQUID ASSETS AND TIME DEPOSITS) AMOUNTED TO EUR 71.4 M AT END OF YEAR (2017: EUR 51.7 M).  Full Article

Medigene Enters Into Exclusive License Agreement With Helmholtz Zentrum Munich
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Medigene AG ::HAS ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH HELMHOLTZ ZENTRUM MUNICH (HMGU).LICENSE AGREEMENT FOR A CHIMERIC CO-STIMULATORY RECEPTOR WHICH IS A FUSION PROTEIN OF PD-1 AND 4-1BB.  Full Article

Medigene Publishes Topline Interim Data From Ongoing Phase I/II Clinical Trial
Thursday, 20 Dec 2018 

Dec 19 (Reuters) - Medigene AG ::MEDIGENE PUBLISHES TOPLINE INTERIM DATA FROM ONGOING PHASE I/II CLINICAL TRIAL WITH DC VACCINES IN AML PATIENTS.MEDIGENE SAYS VACCINATIONS WERE WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS (SAES) RELATED TO TREATMENT IN ONGOING TRIAL.  Full Article

Medigene 9-month Net Loss Up 14 Pct To EUR 12.2 Million
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Medigene AG ::9-MONTH TOTAL REVENUE INCREASED BY 11% TO EUR 8.0 MILLION.9-MONTH EBITDA LOSS INCREASED AS ANTICIPATED BY 5% TO EUR 10.7 MILLION.9-MONTH NET LOSS INCREASED BY 14 % TO EUR 12.2 MILLION DUE TO HIGHER RESEARCH AND DEVELOPMENT EXPENSES AND CURRENCY EFFECTS.FURTHER IMPROVEMENT OF FINANCIAL GUIDANCE 2018.CONTINUES TO EXPECT TOTAL REVENUE OF EUR 9.5 - 10.5 MILLION IN 2018.COMPANY NOW EXPECTS TO SPEND EUR 19 - 21 MILLION FOR FULL YEAR 2018 (PREVIOUS GUIDANCE: EUR 21 - 23 MILLION).EXPECTING TO MAKE A LOSS AT EBITDA LEVEL OF EUR 16 - 18 MILLION (PREVIOUS GUIDANCE: EUR 18 - 20 MILLION) IN 2018.FORECASTS A TOTAL CASH USAGE OF EUR 12 - 14 MILLION FOR 2018 (PREVIOUS GUIDANCE: EUR 15 - 17 MILLION).  Full Article

BRIEF-Medigene Enters Phase I Clinical Development With Its Tcr-T Immunotherapy Mdg1021 In Hematological Cancers

* PTA-NEWS: MEDIGENE AG: MEDIGENE ENTERS PHASE I CLINICAL DEVELOPMENT WITH ITS TCR-T IMMUNOTHERAPY MDG1021 IN HEMATOLOGICAL CANCERS